Suiyang Liu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Suiyang Liu

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

Bioengineering & Translational Medicine|September 11, 2023

Quatramer™ encapsulation of dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancerSachchidanand Tiwari, Suiyang Liu, Mohd Anees, et al.

British Journal of Cancer|February 5, 2020

Inhibition of the deubiquitinase USP10 induces degradation of SYKJing Yang, Chengcheng Meng, Ellen Weisberg, et al.

Journal of Medicinal Chemistry|March 28, 2020

Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC InhibitorsAshish Thakur, Gregory J Tawa, Mark J Henderson, et al.

Leukemia|August 29, 2019

Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.

Leukemia|March 8, 2020

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.

Genes & Cancer|December 25, 2012

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsErik A Nelson, Sarah R Walker, Michael Xiang, et al.

Pageof 2

Search research articles

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

Bioengineering & Translational Medicine|September 11, 2023

Quatramer™ encapsulation of dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancerSachchidanand Tiwari, Suiyang Liu, Mohd Anees, et al.

British Journal of Cancer|February 5, 2020

Inhibition of the deubiquitinase USP10 induces degradation of SYKJing Yang, Chengcheng Meng, Ellen Weisberg, et al.

Journal of Medicinal Chemistry|March 28, 2020

Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC InhibitorsAshish Thakur, Gregory J Tawa, Mark J Henderson, et al.

Leukemia|August 29, 2019

Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.

Leukemia|March 8, 2020

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemiaEllen Weisberg, Chengcheng Meng, Abigail Case, et al.

Genes & Cancer|December 25, 2012

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsErik A Nelson, Sarah R Walker, Michael Xiang, et al.

Pageof 2